ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies (Innolink: 101.951 IP-LS)

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

61685.1 IP-LS

Projekttitel

ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies (Innolink: 101.951 IP-LS)

Projekttitel Englisch

ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies (Innolink: 101.951 IP-LS)

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Deutsch)	ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies (Innolink: 101.951 IP-LS)
Kurzbeschreibung (Englisch)	ONCONIX: A revolutionary organoid culturing and drug efficacy testing platform for personalized response prediction to cancer therapies
Abstract (Deutsch)	We will deliver ONCONIX: a highly innovative personalized treatment-response prediction platform for oncology based on uniquely rapid patient-derived organoid cultures and in-house developed machine learning models. Here, we will perform a non-interventional proof-of-concept study in bladder cancer.